Skip to main content

Specialty Pharmacy

  • FDA requests more data for Baxter, Halozyme biotech treatment

    DEERFIELD, Ill. — The Food and Drug Administration is requesting additional data from two drug makers for a treatment for immune system disorders.

    Baxter and Halozyme said the FDA wanted more data to review their application for HyQ, a combination of immune globulin and recombinant human hyaluronidase.

    The companies said they would work to develop studies to provide additional data to address the agency's concerns.

     

  • Merck, Endocyte sign deal to develop cancer drug

    WHITEHOUSE STATION, N.J. — Two drug makers have signed a deal to develop an experimental drug for treating two types of cancer.

    Merck and Endocyte announced that they would develop and commercialize the latter's drug EC145 (vintafolide), currently in a phase-3 trial, as a treatment for platinum-resistant ovarian cancer and a phase-2 trial for non-small cell lung cancer. Both studies are also using Endocyte's experimental diagnostic agent, EC20 (etarfolatide).

  • Filling the need for specialty Rx

    With the rise in people diagnosed with complex illnesses like cancers, multiple sclerosis, rheumatoid arthritis, hepatitis, Crohn’s disease and rare genetic disorders, the need for specialty pharmacies to deal with the complex drug regimens they require will rise as well.


  • Targeting diabetes with loyalty cards

    One of the highlights for Rite Aid’s business has been Wellness+, its loyalty card program that has played a major role in driving growth in the company’s comps, as well as attracting new and more loyal customers.


  • Drug makers invested $49.5 billion in R&D in 2011, report finds

    WASHINGTON — Drug companies invested nearly $50 billion in research and development in 2011, according to a new report by a drug industry trade group.

  • Walmart, Humana team up for Rx4Value program

    BENTONVILLE, Ark. — Walmart and healthcare partner Humana are out with a new prescription drug program called Rx4Value that guarantees savings and relies on the proven strategy of improving affordability by restricting choice to generic drugs.

  • Diplomat appoints Gary Rice as VP clinical services

    FLINT, Mich. — Diplomat Specialty Pharmacy has appointed a longtime specialty pharmacy executive to its executive team, the company said Thursday.

    Diplomat announced that it had made Gary Rice its VP clinical services. Rice had previously worked as Diplomat's director of clinical services.

  • Valeant acquires Pedinol

    MONTREAL — Valeant announced that it has acquired a privately owned specialty pharmaceutical company based in the United States.

    Pedinol Pharmacal, a podiatry-focused company that has been in business for more than 85 years, was acquired for an undisclosed amount that was said to be 1.5 times sales. Pedinol touted $18 million in revenue last year.

X
This ad will auto-close in 10 seconds